Fritextsökning
Artiklar per år
Innehållstyper
-
New diagnostic test soon ready for the market
-
Ziccum byter till First North och hoppas på covidsamarbete
När covidvaccin ska börja ges i stor skala kommer miljardtals sprutor behöva tas omhand. Svenska Ziccum anser att deras teknik kan användas för att minska det problemet
-
Att ta en produkt från utveckling till kommersialisering
-
Scibase diagnosverktyg tar hjälp av ny AI
Når större marknad med produkt för analys av hudbarriären.
-
Reumaläkemedel ska testas mot covid-19
Det svensk-danska företaget Synact Pharma startar nu fas II-studier med sin läkemedelskandidat mot covid-19.
-
Ny Nordamerikachef hos Calliditas
Andrew Udell har utsetts till ny chef för Calliditas Therapeutics verksamhet i Nordamerika.
-
Helena Strigård: The rise of the community
Sweden Bio´s CEO is looking back at the last decade of development in the industry. Something has shifted in the interdependence between small and larger companies.
-
Intervju: ”Vi har blivit ett mer moget bolag”
Xspray Pharma byter börslista – ”Skulle kunna ta runt halva marknaden på bara ett par veckor”
-
Pilots want to live too
-
Krönika: Collaboration across borders
-
Swedish and Danish Life Science – are there still untapped synergies?
With the increasing developments in life sciences over the past decade and strong support for the sector’s strategic importance from both the Sweden and Danish governments, the timing of The Future of Swedish & Danish Life Science conference could not be better. A one-day conference on ongoing collaborations, new directions and required future investment will held on April 2nd at Medicon Village in Lund.
-
MSD knoppar av verksamhet
Skapar spinoff-bolag för att lägga större fokus på sina fyra största tillväxtpelare och sin utvecklingspipeline.
-
A world-class research village
Eight years ago, Medicon Village was set up in Lund. Since then, this hub for research, innovation and business has developed enormously, and today the life science village is home to over 150 organisations, employing more than 2,200 people.
-
Krönika: Can regulators keep up with innovation?
New technology has increased the understanding of disease mechanisms and enabled approval of products targeting small but specific patient populations; sometimes referred to as precision medicine. Gene- and cell therapies have reached the market
-
Brexit looking back and looking forward
More than 3 years have passed after the vote and there is still uncertainty around the outcome although the UK December 12 election set a clearer course towards an exit early 2020.